[O-31] Oral Session 31
Clinical trial and Regenerative medicine 1 E

[O-31-4] Satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder

^○Anthony Traboulsee¹, Benjamin Greenberg², Jeffrey L. Bennett³, Lech Szczechowski⁴, Edward Fox⁵, Svitlana Shkrobot⁶, Takashi Yamamura⁷, Yusuke Terada⁸, Yuichi Kawata⁸, Pádraig Wright⁹, H.-christian Von Büdingen¹⁰, Gaelle Klingelschmitt¹⁰, Athos Gianella-borradori¹¹, Brian G. Weinshenker¹² (1.University of British Columbia, Canada, 2.University of Texas Southwestern Medical Center, 3.University of Colorado School of Medicine, 4.Silesian Centre of Neurology, 5.Central Texas Neurology Consultants, 6.Ternopil State Medical University, 7.National Center of Neurology and Psychiatry, 8.Chugai Pharmaceutical Co., Ltd, Tokyo, 9.Chugai Pharma Europe Ltd. London, 10.F. Hoffmann-La Roche Ltd, 11.Chugai Pharma USA LLC, 12.Mayo Clinic)